Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
-

Ratings ESG MSCI

Ratings Bio-Rad Laboratories, Inc.: Strengths and Weaknesses

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation
Highlights: Bio-Rad Laboratories, Inc.
  • The company is in a robust financial situation considering its net cash and margin position.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses: Bio-Rad Laboratories, Inc.
  • The company's earnings growth outlook lacks momentum and is a weakness.
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 46.86 times its estimated earnings per share for the ongoing year.
  • Most analysts recommend that the stock should be sold or reduced.
  • The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
  • Over the past twelve months, analysts' opinions have been revised negatively.
  • The group usually releases earnings worse than estimated.

Rating Financials

Bio-Rad Laboratories, Inc. SectorUnited States

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

-

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

-

Long Term balance sheet growth

-

Long term revenue growth

Long term EPS growth

-
More ratings

Rating Valuation

Bio-Rad Laboratories, Inc. SectorUnited States

Global Valuation

-

Enterprise Value

EV/Revenue

EV/EBITDA

EV/FCF

-

Equity Valuation

-

P/E

PBR

-

Dividend Yield

-

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

Bio-Rad Laboratories, Inc. SectorUnited States

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

-

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Bio-Rad Laboratories, Inc. SectorUnited States

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Bio-Rad Laboratories, Inc. SectorUnited States

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
10.31B - -
201B
BBB
117B
BBB
62.6B
AA
52.49B
AAA
51.69B
A
33.65B
BBB
31.27B
A
24.52B
AA
24.05B
AA
Average 60.82B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. BIO Stock
  4. BIO.B Stock
  5. Ratings Bio-Rad Laboratories, Inc.